FDA Approves New Weight-Loss Drug Foundayo in Record Time

The expedited approval marks one of the fastest new drug clearances in decades, but the medication carries significant safety risks.

Apr. 5, 2026 at 2:00pm

Got story updates? Submit your updates here. ›

The U.S. Food and Drug Administration has approved a new weight-loss drug called Foundayo (orforglipron) in just 50 days, one of the fastest approvals of a new molecular drug since 2002. The medication, a glucagon-like peptide-1 (GLP-1) receptor agonist, is intended to help regulate appetite and blood sugar to aid weight loss when used alongside diet and exercise changes. However, the drug carries a range of potential side effects, including nausea, vomiting, and a boxed warning for thyroid tumor risk.

Why it matters

The expedited approval of Foundayo signals quicker access to new weight-loss treatments for adults with obesity or related health conditions. However, the drug's fast-track clearance has raised concerns about the thoroughness of safety reviews, as it carries significant side effect risks that patients and doctors will need to carefully weigh.

The details

Foundayo was approved under the FDA's Commissioner's National Priority Voucher pilot program, which allows for closer coordination between regulators and drugmakers and a 'rolling review' process. The approval came 294 days before the drug's original target decision date. In clinical trials, participants who took Foundayo for 72 weeks experienced meaningful weight loss compared to those who received a placebo, but the medication also carries risks of nausea, vomiting, diarrhea, abdominal pain, fatigue, headaches, and more serious issues like inflammation of the pancreas, kidney injury, and thyroid tumors.

  • The FDA approved Foundayo on April 5, 2026.
  • The drug's original target decision date was in early 2027.

The players

Eli Lilly and Company

The pharmaceutical company that manufactures Foundayo and can now begin broader distribution of the new weight-loss drug.

U.S. Food and Drug Administration (FDA)

The federal agency that approved Foundayo through its expedited Commissioner's National Priority Voucher pilot program, marking one of the fastest new drug clearances in decades.

Got photos? Submit your photos here. ›

What’s next

The FDA will hold a public meeting on June 4, 2026 to gather feedback on how the fast-track program operates, including how drugs are selected and reviewed. Written comments will be accepted through June 29, 2026.

The takeaway

The approval of Foundayo highlights the tradeoffs between expedited access to new treatments and thorough safety reviews. While the fast-track program aims to address major health priorities, the drug's significant side effect risks underscore the need for continued public oversight and input on the program's long-term impact.